Quick Take: AstraZeneca Pursues Traditional Chinese Medicine As New Source For R&D
This article was originally published in PharmAsia News
AstraZeneca signs research collaboration with Shanghai’s Fudan University to investigate mechanism of action for a TCM compound to treat cardiovascular disease.
You may also be interested in...
Sanofi-Aventis Asia Pacific R&D Head Frank Jiang On Opportunities In China And India: An Interview With PharmAsia News (Part 1 of 2)
Novartis’ Paul Herrling And En Li On R&D Strategy In China, India And The Pacific Rim: An Interview With PharmAsia News (Part 2 of 2)
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.